ELMSFORD, N.Y., May 8, 2013 /PRNewswire/ -- BioScrip, Inc.
(NASDAQ: BIOS) today announced 2013 first quarter financial
results. First quarter revenue from continuing operations was
$199.1 million and the net loss from
continuing operations was $7.5
million, or $0.13 per diluted
share. Consolidated Adjusted EBITDA for the first quarter was
$11.5 million, and consolidated
Adjusted EPS for the first quarter was $0.04 per diluted share.
(Logo: http://photos.prnewswire.com/prnh/20130117/NY44138LOGO
)
As a result of the sale of the Company's traditional and
specialty pharmacy mail operations and community retail pharmacy
stores on May 4, 2012 (the "Pharmacy
Services Asset Sale"), the Company's financial statements reflect
the discontinued operations' results for the three months ended
March 31, 2013 and 2012 separate from the continuing
operations of the business. The remaining assets and liabilities of
the divested business that were not transferred as a part of the
Pharmacy Services Asset Sale are included in continuing operations.
First Quarter Highlights
- Revenue from continuing operations increased by $43.4 million, or 27.9%, as compared to the prior
year. Revenue from our Infusion Services segment increased by
$45.3 million, or 41.5% as compared
to the prior year;
- Gross profit from continuing operations increased 18.1% to
$63.2 million, or 31.8% of revenue,
from $53.5 million, or 34.4% of
revenue, in the prior year period;
- Adjusted EBITDA from continuing operations increased
$3.1 million, or 37.0% to
$11.5 million, or 5.8% of revenue,
from $8.4 million, or 5.4% in the
prior year period. The performance in the quarter included
investments in growth initiatives, such as increased sales
resources and the development of new market offerings;
- Acquired HomeChoice Partners, Inc. ("HomeChoice"), formerly a
majority-owned subsidiary of DaVita HealthCare Partners Inc. (NYSE:
DVA); and
- Initiated a review of the Company's capital structure to
support its growth strategy.
"We are pleased to report another quarter of solid
performance. Our results reflect the continued execution of
our strategic plan, growing organically and targeting opportunistic
acquisitions that enable us to expand our national infusion
footprint. Our site of service initiatives are providing us with
increased access to patient census and the opportunity for
continued growth as patient care moves to lower-cost settings, such
as the home or alternate sites of administration," said
Rick Smith, President and Chief
Executive Officer of BioScrip.
Results of Operations
First Quarter 2013 versus First Quarter 2012
Revenue
from continuing operations for the first quarter of 2013 totaled
$199.1 million, compared to
$155.6 million for the same period a
year ago, an increase of $43.4
million or 27.9%. Infusion Services segment revenue
was $154.4 million in the first
quarter, as compared to $109.1
million for the same period in 2012. The 41.5%
increase was driven primarily by overall volume growth as well as
additional revenue related to acquisitions. Home Health
Services segment revenue was $17.9
million for the first quarter of 2013, as compared to
$16.7 million in the prior year
quarter. The 7.4% increase was primarily the result of growth
in volume from private duty nursing activity. PBM Services
segment revenue was $26.8 million for
the first quarter of 2013, compared to $29.9
million for the prior year period. The decrease was
due primarily to a reduction in discount card volume.
Consolidated gross profit for the first quarter of 2013 was
$63.2 million, or 31.8% of revenue,
compared to $53.5 million, or 34.4%
of revenue, for the first quarter of 2012. The increase in
gross profit was the result of growth in Infusion Services segment
revenues. The decline in gross profit margin percentage was
mainly the result of business mix.
During the first quarter of 2013, Infusion Services Segment
Adjusted EBITDA was $12.3 million, or
8.0% of segment revenue, compared to $7.8
million, or 7.1% of segment revenue in the prior year
quarter.
The Home Health Services Segment Adjusted EBITDA in the first
quarter of 2013 was $883,000, or 4.9%
of segment revenue, compared to $1.1
million, or 6.5% of segment revenue, in the comparable prior
year period.
The PBM Services Segment Adjusted EBITDA was $6.2 million, or 23.2% of segment revenue, for
the first quarter of 2013 compared to $6.1
million, or 20.4% of segment revenue, in the prior year
quarter.
On a consolidated basis, BioScrip reported $11.5 million of Adjusted EBITDA during the first
quarter of 2013, or 5.8% of total revenue, compared to $8.4 million, or 5.4% of total revenue, in the
same period last year. The performance in the quarter
included investments in growth initiatives, such as increased sales
resources and the development of new market offerings.
Interest expense in the first quarter of 2013 was $6.5 million compared to $6.6 million in the prior year period.
Income tax expense for continuing operations in the first
quarter was $58,000 compared to an
income tax benefit of $502,000 in the
first quarter of 2012.
Net loss from continuing operations for the first quarter of
2013 was $7.5 million, or a loss of
$0.13 per diluted share, compared to
a net loss of $2.0 million, or
$0.04 per diluted share, for the
first quarter of 2012. Adjusted EPS from continuing
operations for the first quarter of 2013 was $0.04 per diluted share, compared to Adjusted EPS
from continuing operations of $0.00
per diluted share, for the first quarter of 2012.
Liquidity and Capital Resources
The Company's cash
balance at the end of the first quarter was zero and outstanding
borrowings under its revolving credit facility was
approximately $28.0 million as it utilized a combination of
its available cash and borrowings under its revolving credit
facility to fund the acquisition of HomeChoice. Subsequent to
the end of the first quarter, the Company raised net proceeds of
$118.6 million from a public offering
of its common stock and used part of such net proceeds to pay down
outstanding amounts under its revolving credit facility.
Outlook
The Company reaffirms its initial 2013 revenue
target of $830.0 million to $865.0
million and 2013 Adjusted EBITDA target of $67.0 million to $73.0 million.
Conference Call
BioScrip will host a conference call
to discuss its first quarter 2013 financial results on May 9, 2013 at 8:30 a.m.
Eastern Time.
Interested parties may participate in the conference call by
dialing 800-705-5308 (US), or 303-223-4377 (International), 5-10
minutes prior to the start of the call. A replay of the conference
call will be available for two weeks after the call's completion by
dialing 800-633-8284 (US) or 402-977-9140 (International) and
entering conference call ID number 21656383. An audio webcast and
archive will also be available for 30 days under the "Investor
Relations" section of the BioScrip website at www.bioscrip.com.
About BioScrip, Inc.
BioScrip, Inc. provides
comprehensive infusion and home care solutions. By partnering with
patients, physicians, healthcare payors, government agencies and
pharmaceutical manufacturers we are able to provide access to
infusible medications and management solutions. Our goal is to
optimize outcomes for chronic and other complex healthcare
conditions and enhance the quality of patient life. BioScrip brings
clinical competence in providing high-touch, comprehensive infusion
and nursing services to patients in the most convenient ways
possible. Through our customer services and treatments we aim to
ensure the best possible therapy outcome.
Forward Looking Statements – Safe Harbor
This press release includes statements that may constitute
"forward-looking statements," including projections of certain
measures of the Company's results of operations, projections
of certain charges and expenses, and other statements
regarding the Company's goals, regulatory approvals and
strategy. These statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. You can identify these statements by the fact that
they do not relate strictly to historical or current facts.
In some cases, forward-looking statements can be identified
by words such as "may," "should," "could," "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe,"
"predict," "potential," "continue" or comparable
terms. Investors are cautioned that any such forward-looking
statements are not guarantees of future performance and, because
such statements inherently involve risks and uncertainties, actual
results may differ materially from those in the forward-looking
statements. Factors that could cause or contribute
to such differences include but are not limited to risks
associated with: the Company's ability to grow its Infusion
Services segment organically or through acquisitions and obtain
financing in connection therewith; its ability to effectively
integrate acquisitions; its ability to reduce operating costs while
sustaining growth; reductions in federal, state and commercial
payor reimbursement for the Company's products and services;
increased government regulation related to the health care and
insurance industries; as well as the risks described in the
Company's periodic filings with the Securities and Exchange
Commission, including the Company's annual report on Form 10-K for
the year ended December 31, 2012. The Company does not
undertake any duty to update these forward-looking statements after
the date hereof, even though the Company's situation may change in
the future. All of the forward-looking statements herein are
qualified by these cautionary statements.
Reconciliation to Non-GAAP Financial Measures
In addition to reporting all financial information required in
accordance with generally accepted accounting principles ("GAAP"),
the Company is also reporting EBITDA, Adjusted EBITDA, and Adjusted
EPS, which are non-GAAP financial measures. EBITDA, Adjusted
EBITDA and Adjusted EPS are not measurements of financial
performance under GAAP and should not be used in isolation or
as a substitute or alternative to net income, operating income or
any other performance measure derived in accordance with GAAP, or
as a substitute or alternative to cash flow from
operating activities or a measure of our liquidity. In addition,
the Company's definitions of EBITDA, Adjusted EBITDA and Adjusted
EPS may not be comparable to similarly titled non-GAAP financial
measures reported by other companies. EBITDA represents net
income before net interest expense, income tax expense,
depreciation and amortization. Adjusted EBITDA, as
defined by the Company, represents net income before net
interest expense, income tax expense, depreciation and
amortization, stock-based compensation expense, acquisition and
integration expenses, and restructuring and other expenses. As part
of restructuring and other expenses, the Company may incur
significant charges such as, but not limited to, the write down of
certain long−lived assets, temporary redundant expenses, retraining
expenses, potential cash bonus payments and potential accelerated
payments or terminated costs for certain of its contractual
obligations. Adjusted EPS, as defined by the Company, represents
earnings per diluted share, excluding the same elements in
calculating Adjusted EBITDA (restructuring and other expenses,
acquisition and integration expenses, stock-based compensation
expense) as well as the impact of acquisition-related intangible
amortization. Management believes that these non-GAAP
financial measures provide useful supplemental information
regarding the performance of our business operations and
facilitates comparisons to our historical operating results. For a
full reconciliation of EBITDA, Adjusted EBITDA and Adjusted EPS to
the most comparable GAAP financial measures, please see the
attachments to this earnings release.
(Financial Tables Follow)
Schedule 1
|
BIOSCRIP, INC
|
|
|
|
|
CONSOLIDATED BALANCE SHEETS
|
(in
thousands, except for share amounts)
|
|
|
|
|
|
March 31,
2013
|
|
December 31,
2012
|
ASSETS
|
|
|
|
Current
assets
|
|
|
|
Cash and
cash equivalents
|
$
-
|
|
$
62,101
|
Receivables, less allowance for doubtful accounts of
$21,482 and $22,728 at
December
31, 2012 and December 31, 2011, respectively
|
158,127
|
|
129,103
|
Inventory
|
22,819
|
|
34,034
|
Prepaid
expenses and other current assets
|
9,081
|
|
10,189
|
Total
current assets
|
190,027
|
|
235,427
|
Property
and equipment, net
|
27,767
|
|
23,721
|
Goodwill
|
414,234
|
|
350,810
|
Intangible
assets, net
|
19,364
|
|
17,446
|
Deferred
financing costs
|
2,522
|
|
2,877
|
Investments in and advances to unconsolidated
affiliate
|
10,415
|
|
10,042
|
Other
non-current assets
|
1,385
|
|
2,053
|
Total
assets
|
$
665,714
|
|
642,376
|
LIABILITIES AND STOCKHOLDERS'
EQUITY
|
|
|
|
Current
liabilities
|
|
|
|
Current
portion of long-term debt
|
$
27,992
|
|
953
|
Accounts
payable
|
32,108
|
|
34,438
|
Claims
payable
|
7,599
|
|
7,411
|
Amounts
due to plan sponsors
|
16,303
|
|
18,173
|
Accrued
interest
|
11,575
|
|
5,803
|
Accrued
expenses and other current liabilities
|
37,580
|
|
41,491
|
Total
current liabilities
|
133,157
|
|
108,269
|
Long-term
debt, net of current portion
|
225,372
|
|
225,426
|
Deferred
taxes
|
10,748
|
|
10,291
|
Other
non-current liabilities
|
8,971
|
|
4,981
|
Total
liabilities
|
378,248
|
|
348,967
|
Stockholders' equity
|
|
|
|
Preferred stock, $.0001 par value; 5,000,000
shares authorized; no shares issued or
outstanding
|
—
|
|
—
|
Common
stock, $.0001 par value; 125,000,000 shares authorized; shares
issued:
59,695,646
and 59,600,713, respectively; shares outstanding: 57,113,126
and
57,026,957, respectively
|
6
|
|
6
|
Treasury
stock, shares at cost: 2,582,520 and 2,582,520,
respectively
|
(10,311)
|
|
(10,311)
|
Additional
paid-in capital
|
390,983
|
|
388,798
|
Accumulated deficit
|
(93,212)
|
|
(85,084)
|
Total
stockholders' equity
|
287,466
|
|
293,409
|
Total
liabilities and stockholders' equity
|
$
665,714
|
|
$
642,376
|
|
Schedule 2
|
BIOSCRIP, INC
|
|
|
|
|
CONSOLIDATED STATEMENTS OF
OPERATIONS
|
(in
thousands, except per share amounts)
|
|
|
|
|
|
Three
Months Ended
|
|
March
31,
|
|
2013
|
|
2012
|
Product
revenue
|
$
150,024
|
|
$
106,803
|
Service
revenue
|
49,047
|
|
48,830
|
Total
revenue
|
199,071
|
|
155,633
|
|
|
|
|
Cost of
product revenue
|
105,533
|
|
72,326
|
Cost of
service revenue
|
30,301
|
|
29,785
|
Total cost
of revenue
|
135,834
|
|
102,111
|
Gross
profit
|
63,237
|
|
53,522
|
% of
revenues
|
31.8%
|
|
34.4%
|
Selling,
general and administrative expenses
|
52,791
|
|
44,575
|
Bad debt
expense
|
3,397
|
|
3,465
|
Acquisition and integration expenses
|
4,623
|
|
172
|
Restructuring and other expenses
|
1,278
|
|
387
|
Amortization of intangibles
|
2,082
|
|
879
|
Income
from operations
|
(934)
|
|
4,044
|
Interest
expense, net
|
6,478
|
|
6,569
|
Net income
(loss) from continuing operations, before income
taxes
|
(7,412)
|
|
(2,525)
|
Tax
provision (benefit)
|
58
|
|
(502)
|
Net income
(loss) from continuing operations, net of income taxes
|
(7,470)
|
|
(2,023)
|
Net income
(loss) from discontinued operations, net of income taxes
|
(658)
|
|
(680)
|
Net income
(loss)
|
$
(8,128)
|
|
$
(2,703)
|
|
|
|
|
Basic
weighted average shares
|
57,047
|
|
55,307
|
Diluted
weighted average shares
|
57,047
|
|
55,307
|
|
|
|
|
Income
(loss) per common share:
|
|
|
|
Basic loss
from continuing operations
|
$
(0.13)
|
|
$
(0.04)
|
Basic
income (loss) from discontinued operations
|
$
(0.01)
|
|
$
(0.01)
|
Basic
income (loss)
|
$
(0.14)
|
|
$
(0.05)
|
|
|
|
|
Diluted
loss from continuing operations
|
$
(0.13)
|
|
$
(0.04)
|
Diluted income (loss) from discontinued
operations
|
$
(0.01)
|
|
$
(0.01)
|
Diluted
income (loss)
|
$
(0.14)
|
|
$
(0.05)
|
|
Schedule 3
|
BIOSCRIP, INC
|
|
|
|
|
CONSOLIDATED STATEMENTS OF CASH
FLOWS
|
(in
thousands)
|
|
|
Three
Months Ended March 31,
|
|
2013
|
|
2012
|
Cash
flows from operating activities:
|
|
|
|
Net income
(loss)
|
$
(8,128)
|
|
$
(2,703)
|
Less:
Income from discontinued operations, net of income taxes
|
(658)
|
|
(680)
|
Loss from
continuing operations, net of income taxes
|
(7,470)
|
|
(2,023)
|
Adjustments to reconcile net income (loss) to net
cash provided by (used in) operating activities:
|
|
|
|
Depreciation
|
2,459
|
|
1,931
|
Amortization of intangibles
|
2,082
|
|
879
|
Amortization of deferred financing costs
|
356
|
|
284
|
Change in
deferred income tax
|
457
|
|
(300)
|
Compensation under stock-based compensation
plans
|
1,973
|
|
966
|
Loss on
disposal of fixed assets
|
13
|
|
23
|
Changes in
assets and liabilities, net of acquired business:
|
|
|
|
Receivables, net of bad debt expense
|
(16,526)
|
|
(16,761)
|
Inventory
|
13,199
|
|
4,215
|
Prepaid
expenses and other assets
|
4,787
|
|
4,238
|
Accounts
payable
|
(2,822)
|
|
5,587
|
Claims
payable
|
187
|
|
(6,598)
|
Amounts
due to plan sponsors
|
(4,140)
|
|
(874)
|
Accrued
expenses and other liabilities
|
(6,745)
|
|
4,557
|
Net cash
provided by (used in) operating activities from continuing
operations
|
$
(12,190)
|
|
$
(3,876)
|
Net cash
provided by (used in) operating activities from discontinued
operations
|
(658)
|
|
6,401
|
Net cash
provided by (used in) operating activities
|
$
(12,848)
|
|
$
2,525
|
Cash
flows from investing activities:
|
|
|
|
Purchases
of property and equipment, net
|
$
(3,655)
|
|
$
(1,547)
|
Cash
consideration paid for asset acquisitions
|
(72,325)
|
|
—
|
Cash
consideration paid to DS Pharmacy
|
—
|
|
(2,935)
|
Cash
consideration paid for unconsolidated affiliate, net of cash
acquired
|
(900)
|
|
—
|
Net cash
provided by (used in) investing activities from continuing
operations
|
(76,880)
|
|
(4,482)
|
Net cash
provided by (used in) investing activities from discontinued
operations
|
—
|
|
2,741
|
Net cash
used in investing activities
|
$
(76,880)
|
|
$
(1,741)
|
Cash
flows from financing activities:
|
|
|
|
Borrowings
on line of credit
|
214,145
|
|
481,151
|
Repayments
on line of credit
|
(187,092)
|
|
(483,224)
|
Repayments
of capital leases
|
(68)
|
|
(35)
|
Net
proceeds from exercise of employee stock compensation
plans
|
642
|
|
1,324
|
Net cash
provided by (used in) financing activities from continuing
operations
|
$
27,627
|
|
$
(784)
|
Net change
in cash and cash equivalents
|
(62,101)
|
|
—
|
Cash
and cash equivalents - beginning of period
|
62,101
|
|
—
|
Cash
and cash equivalents - end of period
|
—
|
|
—
|
|
|
|
|
DISCLOSURE OF CASH FLOW
INFORMATION:
|
|
|
|
Cash paid
during the period for interest
|
$
322
|
|
$
1,241
|
Cash paid
during the period for income taxes
|
$
(6)
|
|
$
197
|
DISCLOSURE OF NON-CASH
TRANSACTIONS:
|
|
|
|
Capital
lease obligations incurred to acquire property and
equipment
|
—
|
|
$
20
|
Schedule 4
|
BIOSCRIP, INC
|
|
Reconciliation between GAAP and Non-GAAP
Measures
|
(in
thousands)
|
|
|
|
|
|
Three
Months Ended
|
|
March
31,
|
|
2013
|
|
2012
|
Results of
Operations:
|
|
|
|
Revenue:
|
|
|
|
Infusion
Services - product revenue
|
$
150,024
|
|
$
106,803
|
Infusion
Services - service revenue
|
4,353
|
|
2,250
|
Total
Infusion Services revenue
|
154,377
|
|
109,053
|
|
|
|
|
Home
Health Services - service revenue
|
17,942
|
|
16,711
|
PBM
Services - service revenue
|
26,752
|
|
29,868
|
|
|
|
|
Total
revenue
|
$
199,071
|
|
$
155,632
|
|
|
|
|
Adjusted
EBITDA by Segment before corporate overhead:
|
|
|
|
Infusion
Services
|
$
12,315
|
|
$
7,783
|
Home
Health Services
|
883
|
|
1,080
|
PBM
Services
|
6,199
|
|
6,098
|
Total
Segment Adjusted EBITDA
|
19,397
|
|
14,961
|
|
|
|
|
Corporate
overhead
|
(7,916)
|
|
(6,582)
|
Consolidated Adjusted EBITDA
|
11,481
|
|
8,379
|
|
|
|
|
Interest
expense, net
|
(6,478)
|
|
(6,569)
|
Income tax
(expense) benefit
|
(58)
|
|
502
|
Depreciation
|
(2,459)
|
|
(1,931)
|
Amortization of intangibles
|
(2,082)
|
|
(879)
|
Stock-based compensation expense
|
(1,973)
|
|
(966)
|
Acquisition and integration expenses
|
(4,623)
|
|
(172)
|
Restructuring and other expenses
|
(1,278)
|
|
(387)
|
Net (loss)
income:
|
$
(7,470)
|
|
$
(2,023)
|
|
|
|
|
|
|
|
|
Supplemental Operating Data
|
|
|
|
|
|
|
|
Total
Assets
|
|
|
|
Infusion
Services
|
$
523,857
|
|
$
438,623
|
Home Health Services
|
63,280
|
|
62,403
|
PBM
Services
|
30,909
|
|
36,354
|
Corporate
unallocated
|
45,189
|
|
95,813
|
Assets
from discontinued operations
|
-
|
|
-
|
Assets
associated with discontinued operations, not sold
|
2,479
|
|
9,183
|
Total
|
$
665,714
|
|
$
642,376
|
BIOSCRIP, INC
|
|
Reconciliation between GAAP and Non-GAAP Earnings
Per Share
|
(in
thousands)
|
|
|
|
Three
Months Ended
|
|
|
|
March
31,
|
|
|
|
2013
1,2
|
|
2012
3,4
|
Net income
from continuing operations
|
$
(7,470)
|
|
$
(2,023)
|
|
Non-GAAP
adjustments:
|
|
|
|
|
|
Restructuring and other expenses
|
1,278
|
|
308
|
|
|
Acquisition and integration expenses
|
4,623
|
|
137
|
|
|
Amortization of intangibles
|
2,082
|
|
699
|
|
|
Compensation under stock-based compensation
plans
|
1,973
|
|
769
|
Non-GAAP
net income from continuing operations
|
$
2,486
|
|
$
(110)
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share from continuing operations, basic and diluted
|
$
(0.13)
|
|
$
(0.04)
|
|
Non-GAAP
adjustments:
|
|
|
|
|
|
Restructuring and other expenses
|
0.02
|
|
0.01
|
|
|
Acquisition and integration expenses
|
0.08
|
|
-
|
|
|
Amortization of intangibles
|
0.04
|
|
0.01
|
|
|
Compensation under stock-based compensation
plans
|
0.03
|
|
0.02
|
Non-GAAP
earnings per share from continuing operations, basic and
diluted
|
$
0.04
|
|
$
-
|
|
|
|
|
|
|
Weighted
average shares outstanding, basic
|
57,047
|
|
55,307
|
Weighted
average shares outstanding, diluted
|
58,509
|
|
55,307
|
Schedule 4
|
BIOSCRIP, INC
|
|
Reconciliation between GAAP and Non-GAAP Earnings
Per Share
|
(in
thousands)
|
|
|
(1)
|
For the
three months ended March 31, 2013 non-GAAP net income from
continuing operations adjustments are net of tax, calculated using
an annual effective tax rate offset by the effect of our net
operating loss carryforwards. The tax expense netted against
restructuring and other expenses, acquisition and integration
expenses, amortization of intangibles, and stock-based compensation
expense was zero for each, respectively.
|
|
(2)
|
For the
three months ended March 31, 2013, non-GAAP Adjusted EPS per basic
and diluted share from continuing operations adjustments are net of
tax, calculated using an annual effective tax rate method offset by
the effect of our net operating loss carryforwards. The tax
expense per basic and diluted share netted against restructuring
and other expenses, acquisition and integration expenses,
amortization of intangibles, and stock-based compensation expense
was $(0.00) per share, respectively.
|
|
(3)
|
For the
three months ended March 31, 2012, non-GAAP net income from
continuing operations adjustments are net of tax, calculated using
an annual effective tax rate offset by the effect of our net
operating loss carryforwards. The tax expense netted against
restructuring and other expenses, acquisition and integration
expenses, amortization of intangibles, and stock-based compensation
expense was $79, $35, $180 and $197 respectively.
|
|
(4)
|
For the
three months ended March 31, 2012, non-GAAP Adjusted EPS per basic
and diluted share from continuing operations adjustments are net of
tax, calculated using an annual effective tax rate offset by
the effect of our net operating loss carryforwards. The tax
expense per basic and diluted share netted against restructuring
and other expenses, acquisition and integration expenses,
amortization of intangibles, and stock-based compensation expense
was $(0.00) per share, respectively.
|
SOURCE BioScrip, Inc.